Review
Open access
Aug 2026
Bracing for the storm: emerging resistance mechanisms to KRAS inhibitors in pancreatic cancer and strategies to overcome them
Current knowledge on molecular resistance to RAS-directed inhibitors in PDAC is summarized, organized into five categories: intrinsic resistance, KRAS-dependent mechanisms, KRAS-independent bypass signaling, downstream pathway reactivation, and tumor microenvironment (TME)-mediated resistance.
M. Pagano Mariano, Enrica Sgarilli, Dirk Mijnlieff et al.
· Cancer Drug Resistance · 0 citations